
|Articles|August 11, 2016
FDA Grants Nivolumab Priority Review in Head and Neck Cancer
Author(s)Bobby Lazzara, MD
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses the recent priority review of nivolumab for use in metastatic head and neck cancer.
Advertisement
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses the recent priority review of nivolumab for use in recurrent or metastatic head and neck cancer, based on results of the CheckMate-141 study.
The study found that nivolumab improved overall survival (7.5 vs 5.1 months) over investigator’s choice.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Subcutaneous Daratumumab Combination in NDMM
2
Developers Resubmit NDA for Rivoceranib/Camrelizumab in Unresectable HCC
3
Trispecific Antibody Earns FDA Fast Track Designation in Multiple Myeloma
4
FDA Grants BTD to Bezuclastinib Combo in Gastrointestinal Stromal Tumors
5



































